Thu, Dec 18, 2014, 4:00 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • incas58 incas58 May 5, 1998 10:55 PM Flag

    Hey Rhaugland, caught your post over on

    lurk but am too cheap to post.

    <To
    Vertex followers, does anyone out there having an
    explanation for the increase in short interest (days to cover
    almost doubled from February to April). Is there some
    negative info already out there???
    If I am not wrong
    Vertex will present additional Phase II data at the
    World AIDS Conference in Geneva.
    Having that in
    mind isn't it strange to see all these shorts?? Thanks
    for your comments, Richie3>

    Here's the
    answer: the short interest is almost exactly the same.
    The avg daily volume is about 1/2. Thus, twice the
    cover ratio.

    That's the math. As for Geneva, the
    data will not be headline stuff; merely add'l data on
    ongoing trials (later endpoints). It's likely to get a
    piece of the pie (see earlier posts by SkinK) as it
    will be "new" and for salvage, new is better than old,
    even taking into account resistance etc. But as Fribon
    points out approval is not imminent (filing hasn't even
    taken place), and it will make less of a splash even
    when it comes. Esp. with drugs like ABT 338 already in
    phase II and moving much faster. Cheers and I guess
    some day I really should fork over the dough to post
    on SI.

 
VRTX
117.73+5.88(+5.26%)3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.